Immuno-oncology Drugs Market Poised to Surpass the US$ 37,783.6 Million Threshold over the Forecast Period By 2027 | CAGR: 16.5%: Coherent Market

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/1271

The global immuno-oncology drugs market, by drug type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy), by cancer type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), was valued at US$ 11,060.6 Mn in 2019 and is expected to exhibit a CAGR of 16.5% over the forecast period (2020-2027). 

The global immune-oncology drugs market has gained significnat traction in the recent past, buoyed by pivotal factors, such as burgeoning prevalence of cancer, innovative product launches, and a robust pipeline of drugs. Key manufacturers in this market have been making R&D investments for the development of novel immune-oncology therapies, besides upgrading the available immune-oncology drugs for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) received regulatory approval in 2017 as an immune checkpoint inhibitor, which blocks the interaction of PD-L1 with PD-1 and CD80. Subsequently, in December 2017, Bristol-Myers Squibb received approval for its Nivolumab (Opdivo) for the adjuvant treatment of melanoma. In August 2017, Novartis received approval for the CAR-T therapy, known as Kymriah, indicated for children and young adults suffering from B- cell lymphoblastic lymphoma. Furthermore, in October 2017, Gilead Life Science acquired Kite pharma Ltd., after the company’s CAR-T therapy Yescarta received the U.S. FDA approval.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1271

These days, the leading market players, as well as small- and mid-sized players, are dynamically participating in R&D programs to support the global immuno-oncology drugs market growth. For instance, in January 2018, Feldan Therapeutics and Green Cross LabCell joined hands to develop natural killer cell-based immunotherapies. In January 2018, OBI Pharma initiated Phase 1 Trial of immunotherapy candidate OBI-888 in advanced solid tumor patients. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in the Phase 2 trial.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1271

A multitude of immuno-oncology combination therapies are currently undergoing extensive research for various cancer indications. In January 2018, the U.S. FDA granted the breakthrough therapy status to the Lenvima-Keytruda drug combination for the treatment of advanced kidney cancer. Furthermore, in February 2018, the Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. In January 2018, Celgene Corporation announced the acquisition of Juno Therapeutics, Inc. to gain access to the novel CAR-T therapy, which is presently in the pipeline. Furthermore, Amgen, Inc. received FDA approval, for Imlygic in 2017, which is an oncolytic virus to treat melanoma.

View Press Release For More Information @ https://bit.ly/3aPg55L

Key Takeaways of the Global Immuno-Oncology Drugs Market:

• Bristol Myers Squibb, Novartis, and Pfizer, Inc. are some of the key companies that are working on the development of innovative immune-oncology therapies. This is a significant growth propeller for the global market.
• The U.S. FDA has approved several immune checkpoint inhibitors, including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1), and Tecentriq (anti-PD-L1).
• Research partnerships and collaborations to develop new drugs by various market players are contributing to the global market expansion.
• The prominent contenders of the global immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

Other Exclusive Reports:

Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2020 – 2027

U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02–Minocycline), By Route of Administration (Oral and Topical), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Size, Share Outlook, and Opportunity Analysis, 2020 – 2030

Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 (NF1) and Neurofibromatosis 2 (NF2), and Schwannomatosis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.